Horizon Oncology Research, LLC,

Lafayette, Indiana 47905

0 studies enrolling now · 10 studies all time

What they study most

Advanced Tumors, Breast Adenocarcinoma, Cancer, Cancer Metastatic, Cervical Cancer, Clear Cell Renal Cell Carcinoma, Erdheim-Chester Disease, Esophageal Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hormone Receptor Positive, Melanoma, Mesothelioma

Studies at this site

• An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors — Recruiting now
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) — Running, not enrolling
• Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer — Completed
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery — Completed
• Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer — Running, not enrolling
• Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types — Stopped early
• Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC — Stopped early
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors — Stopped early
• A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors — Stopped early
• Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer — Completed